-
'Separating science from hope': AAOS' biologic initiative to inform surgeons of approval status
The American Academy of Orthopaedic Surgeons on Oct. 15 introduced the AAOS Biologics Dashboard to help physicians keep up to date with the approval status of biologic innovations. -
FDA warns stem cell clinic about marketing claims, unapproved uses
A Wisconsin stem cell clinic has been cautioned by the FDA for marketing intrathecal and intravenous injections of human stem cell and tissue-based products for a variety of neurologic conditions, according to the Regulatory Affairs Professionals Society. -
Biologica Technologies introduces product for bone regeneration
Orthobiologic company Biologica Technologies on Oct. 6 launched OsseoGen, a cellular bone matrix designed for bone regeneration. -
Aziyo Biologics hires CFO with 20+ years of experience
Regenerative medicine company Aziyo Biologics on Sept. 28 appointed Matthew Ferguson as CFO. -
$2M grant awarded to Histogen to study knee cartilage regeneration
Regenerative medicine company Histogen has received a $2 million grant to help fund a clinical trial for knee cartilage regeneration. -
Dr. Rick Placide implants 1st Signafuse strips during lumbar spinal fusion
Richmond, Va.-based VCU Health spine surgeon Rick Placide, MD, implanted the first Signafuse strips in a patient during a posterolateral lumbar fusion, according to a Sept. 2 news release. -
6 recent orthobiologic advancements in spine surgery
A number of emerging biologic technologies are currently being evaluated and launched in the spine field. Here are six key developments in the past month: -
1st patient treated in Kuros Biosciences spinal fusion trial
Orthobiologics company Kuros Biosciences has treated the first patient in its clinical trial evaluating Fibrin-PTH for transforaminal lumbar interbody fusion in patients with degenerative disc disease. -
Royal Biologics acquisition strengthens spinal fusion portfolio
Orthobiologics company Royal Biologics acquired the Fibrinet system from Vertical Spine Sept. 1. -
$50M raised by DiscGenics to support expansion plans, clinical trials
Biopharmaceutical company DiscGenics has raised $50 million in a Series C funding round, according to an Aug. 25 news release. -
$2.8M+ NIH grant awarded to Steadman Philippon Research Institute for stem cell research
The Steadman Philippon Research Institute in Vail, Colo., has received a grant from the National Institutes of Health to study the use of bone marrow stem cells to delay osteoarthritis in the knee. -
FDA approves 3rd drug for spinal muscular atrophy
The FDA has cleared Genentech's Evrysdi drug for spinal muscular atrophy in adults and children 2 months of age and older, according to an Aug. 10 announcement. -
Biologic Association enrolls 6,000+ members
More than 6,000 members have joined the Biologic Association within the first six months of its website launch. -
Bioventus, Cerapedics & more: 8 orthobiologic companies making waves in 2020
Since the beginning of the year, Becker's Spine Review has reported on eight orthobiologic and regenerative medicine companies that have launched new products, received FDA clearances and demonstrated favorable outcomes in clinical trials: -
Cerapedics reduces number of patients for TLIF bone graft clinical trial
Orthobiologics company Cerapedics received FDA approval to reduce the number of patients required for its P-15L bone graft clinical trial. -
Spine Wave introduces new allograft
Spinal implant developer Spine Wave has launched its Tempest Allograft Bone Matrix, according to a July 14 news release. -
Bioventus invests $15M in CartiHeal with option for acquisition
Orthobiologics company Bioventus said July 16 that it has invested $15 million in CartiHeal and agreed on an option structure to acquire the company pending approval of its Agili-C implant. -
Baxter bone graft gets green light for spine surgery
Orthobiologics company Baxter has received FDA clearance July 9 for its Altapore Shape Bioactive Bone Graft for spine surgery, according to Biospace. -
Aziyo Biologics launches bone matrix for orthopedic surgery
Regenerative medicine company Aziyo Biologics on June 29 launched OsteoGro V, a viable cell bone matrix to assist with bone repair. -
Bioventus launches new-look bone graft for complex spine surgery
Orthobiologics company Bioventus on June 25 launched its Signafuse bioactive bone graft in a strip format.
Page 12 of 34